KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Other Operating Expenses (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Other Operating Expenses for 15 consecutive years, with $128000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses rose 33.33% year-over-year to $128000.0, compared with a TTM value of $909000.0 through Sep 2025, down 64.44%, and an annual FY2024 reading of $1.8 million, up 116.18% over the prior year.
  • Other Operating Expenses was $128000.0 for Q3 2025 at TherapeuticsMD, up from $96000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $143.4 million in Q2 2022 and bottomed at -$93.3 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $5.7 million, with a median of $169000.0 recorded in 2023.
  • The sharpest move saw Other Operating Expenses tumbled 458.82% in 2021, then skyrocketed 1054.84% in 2024.
  • Year by year, Other Operating Expenses stood at -$93.3 million in 2021, then skyrocketed by 110.38% to $9.7 million in 2022, then crashed by 94.45% to $537000.0 in 2023, then dropped by 6.52% to $502000.0 in 2024, then tumbled by 74.5% to $128000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for TXMD at $128000.0 in Q3 2025, $96000.0 in Q2 2025, and $183000.0 in Q1 2025.